Abstract

Materials and Methods We included 132 subjects (88 men) with a mean age of 64.57 years and median T2DM duration of 14.5 years. Skin AGEs were measured with AGE reader mu connect (Diagnoptics) on the dominant arm. The device enables single and automated triplicate measurements: both of these were performed. DSPN was diagnosed through the neuropathy disability score (NDS). Small nerve fibre function was assessed by temperature and pinprick sensation on the foot. Bilateral measurement of the vibration perception threshold (VPT) on the hallux was carried out by using a neurothesiometer (Horwell Scientific Laboratory Supplies). Results Single and triplicate AGE measurements were positively correlated with each other (Pearson's correlation coefficient r = 0.991, 95%CI = 0.987-0.994, p < 0.001). AGEs were higher among subjects with vs. those without DSPN (p < 0.001). Furthermore, they were higher among subjects with reduced vs. normal temperature sensation (p < 0.001), among subjects with reduced vs. normal pinprick sensation (p = 0.002), among those with abnormal vs. normal monofilament examination (p < 0.001), and among those with abnormal vs. normal VPT (p < 0.001). AGEs were correlated with NDS, VPT, and monofilament score. Conclusions In T2DM, skin AGEs are increased in the presence of DSPN. This holds true both for large and for small nerve function impairment. Moreover, AGEs are correlated with DSPN severity.

Highlights

  • Diabetic neuropathy remains a major chronic complication of diabetes mellitus [1]

  • advanced glycation end products (AGEs) were higher among subjects with vs. those without distal sensorimotor polyneuropathy (DSPN) (3:31 ± 0:73 vs. 2:55 ± 0:56, p < 0:001)

  • In type 2 diabetes mellitus (T2DM), the present study has shown that skin AGEs are increased in the presence of DSPN

Read more

Summary

Introduction

Diabetic neuropathy remains a major chronic complication of diabetes mellitus [1]. It may, in turn, lead to further complications, notably diabetic foot, neuropathic pain, and autonomic failure [2]. AGEs may be measured by the enzyme-linked immunosorbent assay (ELISA), highperformance liquid chromatography (HPLC), mass spectrography, and tissue biopsy or through evaluation of skin autofluorescence [5, 6]. In recent years, their measurement in the skin has attracted considerable interest, because it is noninvasive and accurate [5,6,7]. It has been discussed that skin AGEs measurement might serve as a risk marker of atherosclerotic disease [7, 8] or of microvascular complications of diabetes [6, 9]

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call